kabutan

SanBio Company Limited(4592) Summary

4592
TSE Growth
SanBio Company Limited
1,995
JPY
-25
(-1.24%)
Mar 13, 3:30 pm JST
12.51
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
1,930
Mar 16, 8:47 am JST
Summary Chart Historical News Financial Result
PER
PBR
572
Yield
ー%
Margin Trading Ratio
159.54
Stock Price
Mar 13, 2026
Opening Mar 13, 9:03 am
1,956 JPY 12.29 USD
Previous Close Mar 12
2,020 JPY 12.70 USD
High Mar 13, 2:56 pm
2,010 JPY 12.60 USD
Low Mar 13, 9:26 am
1,945 JPY 12.22 USD
Volume
908,200
Trading Value
1.79B JPY 0.01B USD
VWAP
1970.68 JPY 12.36 USD
Minimum Trading Value
199,500 JPY 1,251 USD
Market Cap
0.16T JPY 0.98B USD
Number of Trades
2,710
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
8,294
1-Year High Oct 17, 2025
46,775
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 10,900 6,555,800 601.45
Feb 27, 2026 9,800 6,841,700 698.13
Feb 20, 2026 9,800 6,962,600 710.47
Feb 13, 2026 26,400 6,739,200 255.27
Feb 6, 2026 25,700 6,841,500 266.21
Company Profile
SanBio Company Limited is a biotech venture specializing in the development of regenerative cell therapies. Their products show promise for treating neurological disorders.
Sector
Pharmaceuticals
SanBio Company Limited is a biotech venture primarily focused on the research and development of regenerative cell medicines. Founded in the United States, the company later expanded into Japan. Their flagship product, SB623, is an allogeneic neural regenerative cell therapy targeting central nervous system disorders. The company has submitted a regulatory application in Japan for chronic traumatic brain injury and aims to expand its indications to include stroke and intracerebral hemorrhage. SanBio possesses proprietary cell culture and manufacturing technologies and has secured product supply rights. Given SB623's strong neuroprotective properties, the company is also exploring its potential in other conditions such as retinal diseases. SanBio employs a business model that combines in-house development with licensing agreements with partner companies. The company places a strong emphasis on securing intellectual property rights and is pursuing a business strategy with global expansion in mind.